Evolving strategies to reduce colectomy rates in primary sclerosing cholangitis-inflammatory bowel disease: clinical remission of corticosteroid refractory colitis post-liver transplant with vedolizumab

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Frontline Gastroenterology

• Publication date

  2016-08-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/flgastro-2016-100711PMID 28839868PMCID PMC5369500
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gut-liver immunity.

  2016cited by this paper
• Management of Ulcerative Colitis Using Vedolizumab After Liver Transplantation for Primary Sclerosing Cholangitis.

  2016cited by this paper
• Treatment of autoimmune liver disease: current and future therapeutic options

  2013cited by this paper
• Mucosal immunity in liver autoimmunity: a comprehensive review.

  2013cited by this paper
• Inflammatory Bowel Disease after Liver Transplantation for Primary Sclerosing Cholangitis

  2013cited by this paper
• Antagonizing the α4β1 Integrin, but Not α4β7, Inhibits Leukocytic Infiltration of the Central Nervous System in Rhesus Monkey Experimental Autoimmune Encephalomyelitis

  2013cited by this paper
• Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease

  2012cited by this paper
• Primary sclerosing cholangitis and disease distribution in inflammatory bowel disease.

  2012cited by this paper
• Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review.

  2012cited by this paper
• Exclusive antagonism of the &agr;4&bgr;7 integrin by vedolizumab confirms the gut‐selectivity of this pathway in primates

  2012cited by this paper
• The safety and efficacy of antitumour necrosis factor‐alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series

  2012cited by this paper
• Anti‐tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients

  2012cited by this paper
• The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases

  2009cited by this paper
• Proctocolectomy for ulcerative colitis after liver transplantation for primary sclerosing cholangitis.

  2009cited by this paper
• Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation

  2008cited by this paper
• Ileal pouch–anal anastomosis and liver transplantation for ulcerative colitis complicated by primary sclerosing cholangitis

  2008cited by this paper
• Proctocolectomy–Ileal Pouch-Anal Anastomosis for Ulcerative Colitis After Liver Transplantation for Primary Sclerosing Cholangitis: A Multi-institutional Analysis

  2008cited by this paper
• Clinically recurrent primary sclerosing cholangitis following liver transplantation: A time course

  2008cited by this paper
• PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis

  2004cited by this paper
• A simple clinical colitis activity index

  1998cited by this paper
• Pouchitis disease course after orthotopic liver transplantation in patients with primary sclerosing cholangitis and an ileal pouch-anal anastomosis.

  1995cited by this paper
• Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis.

  1992cited by this paper
• Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis.

  1991cited by this paper
• Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.

  1987cited by this paper

• Concurrent inflammatory bowel disease and primary sclerosing cholangitis: a review of pre- and post-transplant outcomes and treatment options

  2023cites this paper
• The use of non‐transplant biologics in solid organ transplant recipients: A practical review for the frontline clinician

  2022cites this paper
• Gut-Liver Immune Traffic: Deciphering Immune-Pathogenesis to Underpin Translational Therapy

  2021cites this paper
• Safety of biologic treatments in solid organ transplant recipients: A systematic review.

  2021cites this paper
• Safety of vedolizumab in liver transplant recipients: A systematic review

  2019cites this paper
• Eficacia y seguridad de vedolizumab como opción terapéutica en colitis ulcerosa moderada-grave refractaria en dos pacientes trasplantados hepáticos por colangitis esclerosante primaria

  2017cites this paper
• Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis.

  2017cites this paper